What’s the safety and tolerability of the new enriched synthetic surfactant CHF5633? Associate Editor of ADC FN Jonathan Davis is joined by David Sweet (Royal Maternity Hospital, Belfast) to discuss a first-in-human clinical study of two human surfactant proteins in preterm babies with respiratory distress syndrome. Read the Archives of Disease in Childhood: Fetal & Neonatal's open access paper "A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome": http://fn.bmj.com/content/102/6/F497.